Eli Lilly's New Drug Shows Significant Weight Loss in Women
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Clinical Trial Results: Eli Lilly's experimental obesity drug Foundayo demonstrated significant weight loss in over 1,500 women across ATTAIN-1 and ATTAIN-2 studies, with reductions of up to 14.4% regardless of menopausal status.
- Notable Weight Loss: In the ATTAIN-1 trial, women receiving the highest dose lost an average of 12.7 kg, with 80%-83% achieving at least 5% weight loss, indicating potential improvements in heart disease and diabetes risk factors.
- Waist Circumference Reduction: The treatment also led to waist circumference reductions of up to 4.9 inches (12.45 cm), a critical measure linked to cardiovascular disease and metabolic disorders, underscoring its clinical significance.
- Market Potential Expansion: These findings could help Eli Lilly expand its obesity drug market, particularly among women, a demographic often overlooked, thereby enhancing physician adoption and future regulatory filing prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1125.270
Low
950.00
Averages
1192
High
1500
Current: 1125.270
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo achieved significant weight loss of up to 30.4 lbs (14.4%) over 72 weeks across all stages of menopause, demonstrating the drug's efficacy in weight management.
- Diabetic Patient Outcomes: Even among women with type 2 diabetes, those in ATTAIN-2 experienced significant weight loss, with reductions up to 27.8 lbs (13.6%), indicating Foundayo's effectiveness across varying health conditions.
- Waist Circumference Reduction: Participants in both trials saw meaningful reductions in waist circumference, with decreases of up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2, correlating with reduced abdominal fat and cardiometabolic risk.
- Market Potential: These findings underscore Foundayo's significance in weight management for women, particularly during the often-overlooked menopausal phase, potentially providing Lilly with robust support for further expansion in the obesity treatment market.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Futures Uncertain After Stock Market Rally Breaks Key Support
- Market Rally Falters: Following a stock market rally that failed to maintain key support levels, the outlook for futures has become uncertain, dampening investor confidence and potentially leading to short-term capital outflows.
- Geopolitical Tensions: Iran's missile strikes on Israel have escalated tensions in the Middle East, which could negatively impact global markets, particularly in terms of energy prices and investor sentiment.
- Upcoming Tech IPO: The anticipated SpaceX IPO is generating excitement in the market, with expectations of significant valuation and potential impact, likely attracting considerable investor attention and driving volatility in related tech stocks.
- Earnings Reports Ahead: Apple's advancements in artificial intelligence and Oracle's upcoming earnings report are drawing market focus, as investors look forward to these companies demonstrating strong performance in a competitive landscape.
See More
Eli Lilly's New Drug Shows Significant Weight Loss in Women
- Clinical Trial Results: Eli Lilly's experimental obesity drug Foundayo demonstrated significant weight loss in over 1,500 women across ATTAIN-1 and ATTAIN-2 studies, with reductions of up to 14.4% regardless of menopausal status.
- Notable Weight Loss: In the ATTAIN-1 trial, women receiving the highest dose lost an average of 12.7 kg, with 80%-83% achieving at least 5% weight loss, indicating potential improvements in heart disease and diabetes risk factors.
- Waist Circumference Reduction: The treatment also led to waist circumference reductions of up to 4.9 inches (12.45 cm), a critical measure linked to cardiovascular disease and metabolic disorders, underscoring its clinical significance.
- Market Potential Expansion: These findings could help Eli Lilly expand its obesity drug market, particularly among women, a demographic often overlooked, thereby enhancing physician adoption and future regulatory filing prospects.
See More
Market Rally Breaks Key Support Levels
- Market Rally Analysis: The recent market rally has broken key support levels, indicating volatility in investor sentiment, which may impact short-term trading strategies; investors should closely monitor market dynamics to adjust their portfolios accordingly.
- SpaceX IPO Outlook: SpaceX is set to launch its initial public offering, with high market expectations regarding its valuation and potential impact, as a successful listing could ignite a new wave of investment in the aerospace sector, further boosting related tech stocks.
- Apple's AI Strategy: Apple is ramping up its investments in artificial intelligence, with anticipated new product launches aimed at enhancing its market competitiveness; this strategic shift may attract more investor attention towards its future growth potential.
- Oracle Earnings Forecast: Oracle is about to release its earnings report, with the market keenly focused on its performance; if results exceed expectations, it could drive stock price increases, while disappointing results may trigger market corrections.
See More
Eli Lilly's Foundayo Shows Significant Weight Loss in Women
- Clinical Trial Results: Post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials involving over 1,500 female participants reveal that those taking the highest dose of Foundayo achieved significant weight loss at all stages of menopause, with perimenopausal women losing up to 30.4 lbs (14.4%) and postmenopausal women losing 28.2 lbs (14.1%), highlighting the drug's effectiveness in weight management.
- Impact on Diabetic Patients: In the ATTAIN-2 study, women with type 2 diabetes also experienced significant weight loss across all menopause stages while taking Foundayo, demonstrating the drug's unique advantages in addressing weight loss challenges for this specific population, potentially offering new treatment options.
- Waist Circumference Reduction: Participants in both studies noted meaningful reductions in waist circumference, an important measure linked to decreased abdominal fat and lower cardiometabolic risk, further underscoring Foundayo's potential in improving women's metabolic health.
- FDA Approval and Multiple Indications: Foundayo (orforglipron) is FDA-approved for adults with obesity or weight-related medical issues, and in addition to chronic weight management, it is being studied for potential treatment of type 2 diabetes, obstructive sleep apnea, and other conditions, showcasing its broad clinical application prospects.
See More
Lilly's Foundayo Shows Significant Weight Loss in Menopausal Women
- Clinical Trial Results: In the ATTAIN-1 and ATTAIN-2 trials, women taking Foundayo achieved significant weight loss of up to 30.4 lbs (14.4%) over 72 weeks across all stages of menopause, demonstrating the drug's efficacy in weight management.
- Diabetic Patient Outcomes: Even among women with type 2 diabetes, those in ATTAIN-2 experienced significant weight loss, with reductions up to 27.8 lbs (13.6%), indicating Foundayo's effectiveness across varying health conditions.
- Waist Circumference Reduction: Participants in both trials saw meaningful reductions in waist circumference, with decreases of up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2, correlating with reduced abdominal fat and cardiometabolic risk.
- Market Potential: These findings underscore Foundayo's significance in weight management for women, particularly during the often-overlooked menopausal phase, potentially providing Lilly with robust support for further expansion in the obesity treatment market.
See More
Eli Lilly Reports Positive Phase 3 Results for Retatrutide
- Significant Weight Loss: In the TRIUMPH-1 trial, participants receiving 12 mg of retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30, indicating the drug's potential to transform obesity treatment and market dynamics.
- Improvement in Related Conditions: Retatrutide not only facilitated weight loss but also reduced knee osteoarthritis pain by 4.3 points (73.1%) and the severity of moderate-to-severe obstructive sleep apnea by 36.1 events/hour (60.6%), demonstrating its efficacy across multiple obesity-related conditions.
- Diabetes Management Breakthrough: In the TRANSCEND-T2D-1 trial, retatrutide achieved A1C reductions of up to 2.0% and an average weight loss of 36.6 lbs (16.8%) at 40 weeks, highlighting its significant role in diabetes management and potential market impact.
- Cardiovascular Risk Reduction: In TRIUMPH-1, retatrutide significantly lowered triglycerides by 41%, non-HDL cholesterol by 24.2%, and systolic blood pressure by 12.3 mmHg, suggesting its potential to improve cardiovascular health and broaden market opportunities for the company.
See More
Futures Uncertain After Stock Market Rally Breaks Key Support
- Market Rally Falters: Following a stock market rally that failed to maintain key support levels, the outlook for futures has become uncertain, dampening investor confidence and potentially leading to short-term capital outflows.
- Geopolitical Tensions: Iran's missile strikes on Israel have escalated tensions in the Middle East, which could negatively impact global markets, particularly in terms of energy prices and investor sentiment.
- Upcoming Tech IPO: The anticipated SpaceX IPO is generating excitement in the market, with expectations of significant valuation and potential impact, likely attracting considerable investor attention and driving volatility in related tech stocks.
- Earnings Reports Ahead: Apple's advancements in artificial intelligence and Oracle's upcoming earnings report are drawing market focus, as investors look forward to these companies demonstrating strong performance in a competitive landscape.
See More
Eli Lilly's New Drug Shows Significant Weight Loss in Women
- Clinical Trial Results: Eli Lilly's experimental obesity drug Foundayo demonstrated significant weight loss in over 1,500 women across ATTAIN-1 and ATTAIN-2 studies, with reductions of up to 14.4% regardless of menopausal status.
- Notable Weight Loss: In the ATTAIN-1 trial, women receiving the highest dose lost an average of 12.7 kg, with 80%-83% achieving at least 5% weight loss, indicating potential improvements in heart disease and diabetes risk factors.
- Waist Circumference Reduction: The treatment also led to waist circumference reductions of up to 4.9 inches (12.45 cm), a critical measure linked to cardiovascular disease and metabolic disorders, underscoring its clinical significance.
- Market Potential Expansion: These findings could help Eli Lilly expand its obesity drug market, particularly among women, a demographic often overlooked, thereby enhancing physician adoption and future regulatory filing prospects.
See More
Market Rally Breaks Key Support Levels
- Market Rally Analysis: The recent market rally has broken key support levels, indicating volatility in investor sentiment, which may impact short-term trading strategies; investors should closely monitor market dynamics to adjust their portfolios accordingly.
- SpaceX IPO Outlook: SpaceX is set to launch its initial public offering, with high market expectations regarding its valuation and potential impact, as a successful listing could ignite a new wave of investment in the aerospace sector, further boosting related tech stocks.
- Apple's AI Strategy: Apple is ramping up its investments in artificial intelligence, with anticipated new product launches aimed at enhancing its market competitiveness; this strategic shift may attract more investor attention towards its future growth potential.
- Oracle Earnings Forecast: Oracle is about to release its earnings report, with the market keenly focused on its performance; if results exceed expectations, it could drive stock price increases, while disappointing results may trigger market corrections.
See More
Eli Lilly's Foundayo Shows Significant Weight Loss in Women
- Clinical Trial Results: Post-hoc analyses from the ATTAIN-1 and ATTAIN-2 trials involving over 1,500 female participants reveal that those taking the highest dose of Foundayo achieved significant weight loss at all stages of menopause, with perimenopausal women losing up to 30.4 lbs (14.4%) and postmenopausal women losing 28.2 lbs (14.1%), highlighting the drug's effectiveness in weight management.
- Impact on Diabetic Patients: In the ATTAIN-2 study, women with type 2 diabetes also experienced significant weight loss across all menopause stages while taking Foundayo, demonstrating the drug's unique advantages in addressing weight loss challenges for this specific population, potentially offering new treatment options.
- Waist Circumference Reduction: Participants in both studies noted meaningful reductions in waist circumference, an important measure linked to decreased abdominal fat and lower cardiometabolic risk, further underscoring Foundayo's potential in improving women's metabolic health.
- FDA Approval and Multiple Indications: Foundayo (orforglipron) is FDA-approved for adults with obesity or weight-related medical issues, and in addition to chronic weight management, it is being studied for potential treatment of type 2 diabetes, obstructive sleep apnea, and other conditions, showcasing its broad clinical application prospects.
See More
